Researchers conducted a retrospective review of the state’s hospital data, including more than 1 million patients who were discharged with heart failure during the 11-year period.
Overall, 42,565 of the patients (4 percent) were diagnosed with meth-related heart failure. While heart failure hospitalizations not associated with meth use declined by 6 percent, those related to the drug saw a 585 percent jump.
At the same time, costs for meth-related heart failure saw an even larger increase of 840 percent: Costs rose from $41.5 million in 2008 to $390.2 million by 2018. Researchers attribute the jump to longer hospital stays and more procedures, compared to patients with heart failure unrelated to meth use.
Most meth-related heart failure cases occurred among adults younger than 65 — a concerning trend given heart failure typically occurs among adults older than 60, researchers said.
“The methamphetamine epidemic is often overshadowed by the surge in opioid-related death and illnesses,” said Susan Zhao, MD, lead study author and cardiologist at Santa Clara Valley Medical Center in San Jose, Calif. “The long-term health consequences associated with methamphetamine use require recognition from the public as well as the clinical communities. This study was intended more as a public health alarm: the urgency of methamphetamine use disorder cannot be overstated.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
